India's Dr Reddy's up as analysts see growth from generic GLP-1 launch
** Indian drugmaker Dr Reddy's Laboratories 
DRREDDY rise 2.4% to 1,277 rupees
** Co plans to launch a generic version of Novo Nordisk's 
NOVO_B blockbuster weight-loss drug Wegovy in 87 countries next year
** Co targets early Semaglutide launch in Canada and more than 85 markets ahead of March 2026 expiries
** Jefferies sees Semaglutide as key growth driver;
** Adds, Abatacept IV- an autoimmune drug- launch in January 2027 is also seen boosting growth
** Both products expected to face limited competition and low price erosion- Jefferies
** Jefferies upgrades FY27-28 earnings per share by 10-15% on Semaglutide, Abatacept inclusion
** Co posts narrow Q1 profit miss on U.S. pricing pressure, competition, rev up 11.4% y/y, led by 11% domestic growth
** Goldman Sachs raises its FY26-28 earnings per share view by 3-14%, factors in higher sales in Semaglutide sales in Canada
** YTD, stock down ~10% in 2025 vs a 6.4% rise in Nifty 50 and a 3.8% fall in Nifty pharma index 
CNXPHARMA
